Skip to main content
NCBI home page
Heart logoLink to Heart
. 1999 Oct;82(4):486–493. doi: 10.1136/hrt.82.4.486

Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation

A Tuinenburg 1, I C Van Gelder 1, M P V Den Berg 1, J Brugemann 1, P J De Kam 1, H Crijns 1
PMCID: PMC1760291  PMID: 10490566

Abstract

OBJECTIVE—To investigate the occurrence of heart failure complications, and to identify variables that predict heart failure in patients with (recurrent) persistent atrial fibrillation, treated aggressively with serial electrical cardioversion and antiarrhythmic drugs to maintain sinus rhythm.
DESIGN—Non-randomised controlled trial; cohort; case series; mean (SD) follow up duration 3.4 (1.6) years.
SETTING—Tertiary care centre.
SUBJECTS—Consecutive sampling of 342 patients with persistent atrial fibrillation (defined as > 24 hours duration) considered eligible for electrical cardioversion.
INTERVENTIONS—Serial electrical cardioversions and serial antiarrhythmic drug treatment, after identification and treatment of underlying cardiovascular disease.
MAIN OUTCOME MEASURES—heart failure complications: development or progression of heart failure requiring the institution or addition of drug treatment, hospital admission, or death from heart failure.
RESULTS—Development or progression of heart failure occurred in 38 patients (11%), and 22 patients (6%) died from heart failure. These complications were related to the presence of coronary artery disease (p < 0.001, risk ratio 3.2, 95% confidence interval (CI) 1.6 to 6.5), rheumatic heart disease (p < 0.001, risk ratio 5.0, 95% CI 2.4 to 10.2), cardiomyopathy (p < 0.001, risk ratio 5.0, 95% CI 2.0 to 12.4), atrial fibrillation for < 3 months (p = 0.04, risk ratio 2.0, 95% CI 1.0 to 3.7), and poor exercise tolerance (New York Heart Association class III at inclusion, p < 0.001, risk ratio 3.5, 95% CI 1.9 to 6.7). No heart failure complications were observed in patients with lone atrial fibrillation.
CONCLUSIONS—Aggressive serial electrical cardioversion does not prevent heart failure complications in patients with persistent atrial fibrillation. These complications are predominantly observed in patients with more severe underlying cardiovascular disease. Randomised comparison with rate control treatment is needed to define the optimal treatment for persistent atrial fibrillation in relation to heart failure.


Keywords: atrial fibrillation; cardioversion; heart failure

Full Text

The Full Text of this article is available as a PDF (109.3 KB).

Figure 1  .

Figure 1  

Open in a new tab

Kaplan-Meier plots showing the probability (A) of heart failure event-free survival (that is, free from the development or progression of heart failure) and (B) of not dying of heart failure, in relation to the type of underlying disease. AF, atrial fibrillation; CAD, coronary artery disease; CMP, dilated cardiomyopathy; HF, heart failure; RHD, rheumatic heart disease; UHD, underlying heart disease.

Figure 2  .

Figure 2  

Open in a new tab

Kaplan-Meier plots showing the probability (A) of heart failure event-free survival (that is, free from the development or progression of heart failure) and (B) of not dying of heart failure, in relation to the functional class for exercise tolerance at inclusion (NYHA class I and II, v NYHA class III). HF, heart failure; NYHA, New York Heart Association.

Figure 3  .

Figure 3  

Open in a new tab

Kaplan-Meier plots, showing the probability of maintenance of sinus rhythm in relation to the severity of heart failure at inclusion (A) and the occurrence of a heart failure complication during follow up (B). HF, heart failure; NYHA, New York Heart Association.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benjamin E. J., Levy D., Vaziri S. M., D'Agostino R. B., Belanger A. J., Wolf P. A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994 Mar 16;271(11):840–844. [PubMed] [Google Scholar]
  2. Brand F. N., Abbott R. D., Kannel W. B., Wolf P. A. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA. 1985 Dec 27;254(24):3449–3453. [PubMed] [Google Scholar]
  3. Cameron A., Schwartz M. J., Kronmal R. A., Kosinski A. S. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol. 1988 Apr 1;61(10):714–717. doi: 10.1016/0002-9149(88)91053-3. [DOI] [PubMed] [Google Scholar]
  4. Carlsson J., Tebbe U., Rox J., Harmjanz D., Haerten K., Neuhaus K. L., Seidel F., Niederer W., Miketić S. Cardioversion of atrial fibrillation in the elderly. ALKK-Study Group. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausaerzte. Am J Cardiol. 1996 Dec 15;78(12):1380–1384. doi: 10.1016/s0002-9149(96)00647-9. [DOI] [PubMed] [Google Scholar]
  5. Clark D. M., Plumb V. J., Epstein A. E., Kay G. N. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997 Oct;30(4):1039–1045. doi: 10.1016/s0735-1097(97)00254-4. [DOI] [PubMed] [Google Scholar]
  6. Coplen S. E., Antman E. M., Berlin J. A., Hewitt P., Chalmers T. C. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990 Oct;82(4):1106–1116. doi: 10.1161/01.cir.82.4.1106. [DOI] [PubMed] [Google Scholar]
  7. Crijns H. J., Van Gelder I. C., Tieleman R. G., Brügemann J., De Kam P. J., Gosselink A. T., Bink-Boelkens M. T., Lie K. I. Long-term outcome of electrical cardioversion in patients with chronic atrial flutter. Heart. 1997 Jan;77(1):56–61. doi: 10.1136/hrt.77.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Crijns H. J., Van Gelder I. C., Van Gilst W. H., Hillege H., Gosselink A. M., Lie K. I. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol. 1991 Aug 1;68(4):335–341. doi: 10.1016/0002-9149(91)90828-9. [DOI] [PubMed] [Google Scholar]
  9. Daoud E. G., Weiss R., Bahu M., Knight B. P., Bogun F., Goyal R., Harvey M., Strickberger S. A., Man K. C., Morady F. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol. 1996 Dec 15;78(12):1433–1436. doi: 10.1016/s0002-9149(97)89297-1. [DOI] [PubMed] [Google Scholar]
  10. Feinberg W. M., Blackshear J. L., Laupacis A., Kronmal R., Hart R. G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995 Mar 13;155(5):469–473. [PubMed] [Google Scholar]
  11. Flaker G. C., Blackshear J. L., McBride R., Kronmal R. A., Halperin J. L., Hart R. G. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992 Sep;20(3):527–532. doi: 10.1016/0735-1097(92)90003-6. [DOI] [PubMed] [Google Scholar]
  12. Fowler N. O., van der Bel-Kahn J. M. Indications for surgical replacement of the mitral valve. With particular reference to common and uncommon causes of mitral regurgitation. Am J Cardiol. 1979 Jul;44(1):148–157. doi: 10.1016/0002-9149(79)90264-9. [DOI] [PubMed] [Google Scholar]
  13. Gallagher M. M., Camm A. J. Classification of atrial fibrillation. Pacing Clin Electrophysiol. 1997 Jun;20(6):1603–1605. doi: 10.1111/j.1540-8159.1997.tb03527.x. [DOI] [PubMed] [Google Scholar]
  14. Gosselink A. T., Crijns H. J., Van Gelder I. C., Hillige H., Wiesfeld A. C., Lie K. I. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA. 1992 Jun 24;267(24):3289–3293. [PubMed] [Google Scholar]
  15. Grogan M., Smith H. C., Gersh B. J., Wood D. L. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992 Jun 15;69(19):1570–1573. doi: 10.1016/0002-9149(92)90705-4. [DOI] [PubMed] [Google Scholar]
  16. Heinz G., Siostrzonek P., Kreiner G., Gössinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol. 1992 Feb 15;69(5):489–492. doi: 10.1016/0002-9149(92)90991-7. [DOI] [PubMed] [Google Scholar]
  17. Hohnloser S. H., Kuck K. H. Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial. Pacing Clin Electrophysiol. 1997 Aug;20(8 Pt 1):1989–1992. doi: 10.1111/j.1540-8159.1997.tb03606.x. [DOI] [PubMed] [Google Scholar]
  18. Hoshino P. K., Gaasch W. H. When to intervene in chronic aortic regurgitation. Arch Intern Med. 1986 Feb;146(2):349–352. [PubMed] [Google Scholar]
  19. Kannel W. B., Abbott R. D., Savage D. D., McNamara P. M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982 Apr 29;306(17):1018–1022. doi: 10.1056/NEJM198204293061703. [DOI] [PubMed] [Google Scholar]
  20. Kopecky S. L., Gersh B. J., McGoon M. D., Whisnant J. P., Holmes D. R., Jr, Ilstrup D. M., Frye R. L. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med. 1987 Sep 10;317(11):669–674. doi: 10.1056/NEJM198709103171104. [DOI] [PubMed] [Google Scholar]
  21. Krahn A. D., Manfreda J., Tate R. B., Mathewson F. A., Cuddy T. E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995 May;98(5):476–484. doi: 10.1016/S0002-9343(99)80348-9. [DOI] [PubMed] [Google Scholar]
  22. Likoff M. J., Chandler S. L., Kay H. R. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 1987 Mar 1;59(6):634–638. doi: 10.1016/0002-9149(87)91183-0. [DOI] [PubMed] [Google Scholar]
  23. Maisel W. H., Kuntz K. M., Reimold S. C., Lee T. H., Antman E. M., Friedman P. L., Stevenson W. G. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med. 1997 Aug 15;127(4):281–284. doi: 10.7326/0003-4819-127-4-199708150-00004. [DOI] [PubMed] [Google Scholar]
  24. Nattel S., Hadjis T., Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs. 1994 Sep;48(3):345–371. doi: 10.2165/00003495-199448030-00003. [DOI] [PubMed] [Google Scholar]
  25. Onundarson P. T., Thorgeirsson G., Jonmundsson E., Sigfusson N., Hardarson T. Chronic atrial fibrillation--epidemiologic features and 14 year follow-up: a case control study. Eur Heart J. 1987 May;8(5):521–527. doi: 10.1093/oxfordjournals.eurheartj.a062312. [DOI] [PubMed] [Google Scholar]
  26. Pozzoli M., Cioffi G., Traversi E., Pinna G. D., Cobelli F., Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol. 1998 Jul;32(1):197–204. doi: 10.1016/s0735-1097(98)00221-6. [DOI] [PubMed] [Google Scholar]
  27. Rodriguez L. M., Smeets J. L., Xie B., de Chillou C., Cheriex E., Pieters F., Metzger J., den Dulk K., Wellens H. J. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol. 1993 Nov 15;72(15):1137–1141. doi: 10.1016/0002-9149(93)90982-i. [DOI] [PubMed] [Google Scholar]
  28. Sahn D. J., DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978 Dec;58(6):1072–1083. doi: 10.1161/01.cir.58.6.1072. [DOI] [PubMed] [Google Scholar]
  29. Shapira N., Lemole G. M., Fernandez J., Daily P. O., Dembitsky W. P., O'Yek V., Haghighi P., Stewart J., Marsh D. G., Bloor C. M. Aortic valve repair for aortic stenosis in adults. Ann Thorac Surg. 1990 Jul;50(1):110–120. doi: 10.1016/0003-4975(90)90100-k. [DOI] [PubMed] [Google Scholar]
  30. Stevenson W. G., Stevenson L. W., Middlekauff H. R., Fonarow G. C., Hamilton M. A., Woo M. A., Saxon L. A., Natterson P. D., Steimle A., Walden J. A. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol. 1996 Nov 15;28(6):1458–1463. doi: 10.1016/s0735-1097(96)00358-0. [DOI] [PubMed] [Google Scholar]
  31. Van Gelder I. C., Crijns H. J., Tieleman R. G., Brügemann J., De Kam P. J., Gosselink A. T., Verheugt F. W., Lie K. I. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med. 1996 Dec 9;156(22):2585–2592. doi: 10.1001/archinte.156.22.2585. [DOI] [PubMed] [Google Scholar]
  32. Van Gelder I. C., Crijns H. J., Van Gilst W. H., Verwer R., Lie K. I. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 1991 Jul 1;68(1):41–46. doi: 10.1016/0002-9149(91)90707-r. [DOI] [PubMed] [Google Scholar]
  33. Van den Berg M. P., Tuinenburg A. E., Crijns H. J., Van Gelder I. C., Gosselink A. T., Lie K. I. Heart failure and atrial fibrillation: current concepts and controversies. Heart. 1997 Apr;77(4):309–313. doi: 10.1136/hrt.77.4.309. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES